Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery

Rodrigo A. Ledezma, Edris Negron, Gladell P. Paner, Chris Rjepaj, Danny Lascano, Mohammed Haseebuddin, Pankaj Dangle, Arieh L. Shalhav, Henry Crist, Jay Raman, G. Joel DeCastro, Lara Harik, Monika Paroder, Robert G. Uzzo, Alexander Kutikov, Scott E. Eggener

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: We aimed to determine incidence, pathologic findings, prognostic factors and clinical outcomes for patients with clinically localized papillary RCC. Methods: Demographic, clinical and pathologic findings were collected on all patients with PRCC undergoing surgery at four academic medical centers. The primary endpoint was cancer-specific survival (CSS). Relapse-free survival (RFS) and overall survival (OS) were secondary endpoints. Kaplan–Meier estimates were obtained, and Cox proportional hazard regression models were used to assess predictors of mortality and relapse. Results: We identified 626 PRCC, of which 373 (60 %) were type 1 and 253 (40 %) were type 2, with three-quarters of all tumors being pT1. Compared to patients with type 1, those with type 2 were older (mean age: 63 vs 61; p = 0.02), presented more commonly with symptoms (13 vs 7 %; p = 0.02) and had larger mean tumor size (5.2 vs 4.3 cm; p = 0.001). With a median follow-up of 41 months (IQR: 16–68), 92 patients had died of PRCC (15 %), 48 (8 %) experienced relapse, and 101 died from all causes (16 %). The estimated 5-year CSS, RFS and OS were 83, 91 and 82 %, respectively. In multivariable analysis, older age, T stage and nodal status were predictors of CSS and OS. However, PRCC subtype was not a predictor of CSS, RFS or OS. Conclusion: While patients with type 2 PRCC appear to present with more advanced disease than patients with type 1, PRCC subtype does not appear to be an independent predictor of CSS, RFS or OS for treated localized disease.

Original languageEnglish (US)
Pages (from-to)687-693
Number of pages7
JournalWorld Journal of Urology
Volume34
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Renal Cell Carcinoma
Survival
Recurrence
Neoplasms
Proportional Hazards Models
Demography

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Ledezma, R. A., Negron, E., Paner, G. P., Rjepaj, C., Lascano, D., Haseebuddin, M., ... Eggener, S. E. (2016). Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World Journal of Urology, 34(5), 687-693. https://doi.org/10.1007/s00345-015-1692-3
Ledezma, Rodrigo A. ; Negron, Edris ; Paner, Gladell P. ; Rjepaj, Chris ; Lascano, Danny ; Haseebuddin, Mohammed ; Dangle, Pankaj ; Shalhav, Arieh L. ; Crist, Henry ; Raman, Jay ; Joel DeCastro, G. ; Harik, Lara ; Paroder, Monika ; Uzzo, Robert G. ; Kutikov, Alexander ; Eggener, Scott E. / Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. In: World Journal of Urology. 2016 ; Vol. 34, No. 5. pp. 687-693.
@article{2aaae93479734a38a342a0f017a9767a,
title = "Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery",
abstract = "Purpose: We aimed to determine incidence, pathologic findings, prognostic factors and clinical outcomes for patients with clinically localized papillary RCC. Methods: Demographic, clinical and pathologic findings were collected on all patients with PRCC undergoing surgery at four academic medical centers. The primary endpoint was cancer-specific survival (CSS). Relapse-free survival (RFS) and overall survival (OS) were secondary endpoints. Kaplan–Meier estimates were obtained, and Cox proportional hazard regression models were used to assess predictors of mortality and relapse. Results: We identified 626 PRCC, of which 373 (60 {\%}) were type 1 and 253 (40 {\%}) were type 2, with three-quarters of all tumors being pT1. Compared to patients with type 1, those with type 2 were older (mean age: 63 vs 61; p = 0.02), presented more commonly with symptoms (13 vs 7 {\%}; p = 0.02) and had larger mean tumor size (5.2 vs 4.3 cm; p = 0.001). With a median follow-up of 41 months (IQR: 16–68), 92 patients had died of PRCC (15 {\%}), 48 (8 {\%}) experienced relapse, and 101 died from all causes (16 {\%}). The estimated 5-year CSS, RFS and OS were 83, 91 and 82 {\%}, respectively. In multivariable analysis, older age, T stage and nodal status were predictors of CSS and OS. However, PRCC subtype was not a predictor of CSS, RFS or OS. Conclusion: While patients with type 2 PRCC appear to present with more advanced disease than patients with type 1, PRCC subtype does not appear to be an independent predictor of CSS, RFS or OS for treated localized disease.",
author = "Ledezma, {Rodrigo A.} and Edris Negron and Paner, {Gladell P.} and Chris Rjepaj and Danny Lascano and Mohammed Haseebuddin and Pankaj Dangle and Shalhav, {Arieh L.} and Henry Crist and Jay Raman and {Joel DeCastro}, G. and Lara Harik and Monika Paroder and Uzzo, {Robert G.} and Alexander Kutikov and Eggener, {Scott E.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1007/s00345-015-1692-3",
language = "English (US)",
volume = "34",
pages = "687--693",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "5",

}

Ledezma, RA, Negron, E, Paner, GP, Rjepaj, C, Lascano, D, Haseebuddin, M, Dangle, P, Shalhav, AL, Crist, H, Raman, J, Joel DeCastro, G, Harik, L, Paroder, M, Uzzo, RG, Kutikov, A & Eggener, SE 2016, 'Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery', World Journal of Urology, vol. 34, no. 5, pp. 687-693. https://doi.org/10.1007/s00345-015-1692-3

Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. / Ledezma, Rodrigo A.; Negron, Edris; Paner, Gladell P.; Rjepaj, Chris; Lascano, Danny; Haseebuddin, Mohammed; Dangle, Pankaj; Shalhav, Arieh L.; Crist, Henry; Raman, Jay; Joel DeCastro, G.; Harik, Lara; Paroder, Monika; Uzzo, Robert G.; Kutikov, Alexander; Eggener, Scott E.

In: World Journal of Urology, Vol. 34, No. 5, 01.05.2016, p. 687-693.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery

AU - Ledezma, Rodrigo A.

AU - Negron, Edris

AU - Paner, Gladell P.

AU - Rjepaj, Chris

AU - Lascano, Danny

AU - Haseebuddin, Mohammed

AU - Dangle, Pankaj

AU - Shalhav, Arieh L.

AU - Crist, Henry

AU - Raman, Jay

AU - Joel DeCastro, G.

AU - Harik, Lara

AU - Paroder, Monika

AU - Uzzo, Robert G.

AU - Kutikov, Alexander

AU - Eggener, Scott E.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Purpose: We aimed to determine incidence, pathologic findings, prognostic factors and clinical outcomes for patients with clinically localized papillary RCC. Methods: Demographic, clinical and pathologic findings were collected on all patients with PRCC undergoing surgery at four academic medical centers. The primary endpoint was cancer-specific survival (CSS). Relapse-free survival (RFS) and overall survival (OS) were secondary endpoints. Kaplan–Meier estimates were obtained, and Cox proportional hazard regression models were used to assess predictors of mortality and relapse. Results: We identified 626 PRCC, of which 373 (60 %) were type 1 and 253 (40 %) were type 2, with three-quarters of all tumors being pT1. Compared to patients with type 1, those with type 2 were older (mean age: 63 vs 61; p = 0.02), presented more commonly with symptoms (13 vs 7 %; p = 0.02) and had larger mean tumor size (5.2 vs 4.3 cm; p = 0.001). With a median follow-up of 41 months (IQR: 16–68), 92 patients had died of PRCC (15 %), 48 (8 %) experienced relapse, and 101 died from all causes (16 %). The estimated 5-year CSS, RFS and OS were 83, 91 and 82 %, respectively. In multivariable analysis, older age, T stage and nodal status were predictors of CSS and OS. However, PRCC subtype was not a predictor of CSS, RFS or OS. Conclusion: While patients with type 2 PRCC appear to present with more advanced disease than patients with type 1, PRCC subtype does not appear to be an independent predictor of CSS, RFS or OS for treated localized disease.

AB - Purpose: We aimed to determine incidence, pathologic findings, prognostic factors and clinical outcomes for patients with clinically localized papillary RCC. Methods: Demographic, clinical and pathologic findings were collected on all patients with PRCC undergoing surgery at four academic medical centers. The primary endpoint was cancer-specific survival (CSS). Relapse-free survival (RFS) and overall survival (OS) were secondary endpoints. Kaplan–Meier estimates were obtained, and Cox proportional hazard regression models were used to assess predictors of mortality and relapse. Results: We identified 626 PRCC, of which 373 (60 %) were type 1 and 253 (40 %) were type 2, with three-quarters of all tumors being pT1. Compared to patients with type 1, those with type 2 were older (mean age: 63 vs 61; p = 0.02), presented more commonly with symptoms (13 vs 7 %; p = 0.02) and had larger mean tumor size (5.2 vs 4.3 cm; p = 0.001). With a median follow-up of 41 months (IQR: 16–68), 92 patients had died of PRCC (15 %), 48 (8 %) experienced relapse, and 101 died from all causes (16 %). The estimated 5-year CSS, RFS and OS were 83, 91 and 82 %, respectively. In multivariable analysis, older age, T stage and nodal status were predictors of CSS and OS. However, PRCC subtype was not a predictor of CSS, RFS or OS. Conclusion: While patients with type 2 PRCC appear to present with more advanced disease than patients with type 1, PRCC subtype does not appear to be an independent predictor of CSS, RFS or OS for treated localized disease.

UR - http://www.scopus.com/inward/record.url?scp=84944534255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944534255&partnerID=8YFLogxK

U2 - 10.1007/s00345-015-1692-3

DO - 10.1007/s00345-015-1692-3

M3 - Article

C2 - 26407582

AN - SCOPUS:84944534255

VL - 34

SP - 687

EP - 693

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 5

ER -